The FDA has declared the end of the two-year shortages of Eli Lilly's Mounjaro and Zepbound — used to treat diabetes and weight loss, respectively — and has reaffirmed its decision to halt the ...
The Food and Drug Administration said that a nationwide shortage of Eli Lilly’s Zepbound and Mounjaro has been resolved, eliminating the need for copycat versions of the drugs that have become ...
To approve the generic version of Mounjaro or Zepbound, the FDA will need clear evidence that tirzepatide works as well as the branded medication. Zepbound, which contains the active ingredient ...